BofA Securities analyst Tazeen Ahmad maintains $PTC Therapeutics (PTCT.US)$ with a sell rating, and adjusts the target price from $32 to $30.
According to TipRanks data, the analyst has a success rate of 51.9% and a total average return of 3.9% over the past year.
Furthermore, according to the comprehensive report, the opinions of $PTC Therapeutics (PTCT.US)$'s main analysts recently are as follows:
PTC Therapeutics recently disclosed Q2 results, indicating sales of Translarna at $70.4M and Emflaza also at $70.4M. There is ongoing uncertainty regarding Translarna's continued availability in EU markets following several unfavorable opinions from the Committee for Medicinal Products for Human Use (CHMP). A decisive CHMP opinion is anticipated by mid-October, which could lead to Translarna's withdrawal from EU markets within 67 days if the opinion is adverse. The company's pipeline programs are believed to require further risk reduction.
Estimates on PTC Therapeutics are modestly surpassing the consensus regarding Translarna net product revenues while aligning with expectations on Emflaza net product revenue, according to an analyst overview. The focus for the upcoming discussion will include details about the CHMP re-examination procedures and insights on the submission of further information demanded by the FDA pertaining to the NDA re-submission.
Note:
TipRanks, an independent third party, provides analysis data from financial analysts and calculates the Average Returns and Success Rates of the analysts' recommendations. The information presented is not an investment recommendation and is intended for informational purposes only.
Success rate is the number of the analyst's successful ratings, divided by his/her total number of ratings over the past year. A successful rating is one based on if TipRanks' virtual portfolio earned a positive return from the stock. Total average return is the average rate of return that the TipRanks' virtual portfolio has earned over the past year. These portfolios are established based on the analyst's preliminary rating and are adjusted according to the changes in the rating.
TipRanks provides a ranking of each analyst up to 5 stars, which is representative of all recommendations from the analyst. An analyst's past performance is evaluated on a scale of 1 to 5 stars, with more stars indicating better performance. The star level is determined by his/her total success rate and average return.
美银证券分析师Tazeen Ahmad维持$PTC Therapeutics (PTCT.US)$卖出评级，并将目标价从32美元下调至30美元。
根据TipRanks数据显示，该分析师近一年总胜率为51.9%，总平均回报率为3.9%。
此外，综合报道，$PTC Therapeutics (PTCT.US)$近期主要分析师观点如下：
PTC Therapeutics最近公布了第二季度业绩，显示Translarna的销售额为7,040万美元，Emflaza的销售额也为7.04万美元。在人用药品委员会（CHMP）提出了几项不利意见之后，Translarna在欧盟市场的持续供应仍然存在不确定性。预计CHMP将在10月中旬发表决定性的意见，如果意见不佳，这可能导致Translarna在67天内退出欧盟市场。据信，该公司的管道计划需要进一步降低风险。
分析师的概述显示，对PTC Therapeutics的估计略高于对Translarna净产品收入的共识，同时与对Emflaza净产品收入的预期一致。即将举行的讨论的重点将包括有关CHMP复审程序的详细信息以及对FDA要求提交与重新提交保密协议有关的进一步信息的见解。
提示:
TipRanks为独立第三方，提供金融分析师的分析数据，并计算分析师推荐的平均回报率和胜率。提供的信息并非投资建议，仅供参考。本文不对评级数据和报告的完整性与准确性做出认可、声明或保证。
TipRanks提供每位分析师的星级，分析师星级代表分析师所有推荐的过往表现，通过分析师的总胜率和平均回报率综合计算得出，星星越多，则该分析师过往表现越优异，最高为5颗星。
分析师总胜率为近一年分析师的评级成功次数占总评级次数的比率。评级的成功与否，取决于TipRanks的虚拟投资组合是否从该股票中产生正回报。
总平均回报率为基于分析师的初始评级创建虚拟投资组合，并根据评级变化对组合进行调整，在近一年中该投资组合所获得的回报率。
